CRO Analytics, ACRP Partner To Assess Clinical Trial Quality
CRO Analytics, a provider of validated clinical trial performance data, announced a partnership with the Association of Clinical Research Professionals focused on measuring investigator site personnel views of clinical trial quality
CRO Analytics, a provider of validated clinical trial performance data, announced a partnership with the Association of Clinical Research Professionals (ACRP) focused on measuring investigator site personnel views of clinical trial quality. The collaboration will provide critical insight into the quality of clinical trials, key drivers of that quality, and methods to improve clinical research.
CRO Analytics will develop a statistically validated data collection instrument to be used with the Performer™ platform, and work with ACRP to collect assessments from investigator site personnel. That data will be analyzed using the cloud-based SaaS software application through a series of algorithms and generate benchmarking, key driver analytics, and predictive analytics.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
